Abstract: In this paper we focus on modelling the glucose-insulin dynamics in the human body for the purpose of controlling the glucose level. Due to the fast dynamics in the glucoseinsulin system compared to the natural sampling period (24 h) in a clinical situation, the model structure has to be adapted adequately. This results in a reduced order model with a nonlinear output relation. The development of the estimation methodology is based on a simulation study with a continuous time model. The resulting model structure is used for estimating the parameters of the non-linear system, representing the slow dynamics observed from the slow and sparse sampled clinical data.
INTRODUCTION
Diabetes is a chronic condition characterized by raised levels of glucose in the blood, hyperglycemia. The condition affects more than 425 million people today and the numbers are expected to rise to 693 million by 2045 [International Diabetes Federation 2017] . Poorly managed diabetes can lead to cardiovascular diseases, lower limb amputation, blindness and kidney failure. The American Diabetes Association estimates that care for people with diabetes accounts for more than 20% of all health care expenditure in the U.S. [Petersen 2016 ]. Type 2 diabetes accounts for 90% of all diabetes cases. In type 2 diabetes, the elevated glucose levels are caused by inadequate production and response to the hormone insulin. As opposed to type 1 diabetes, a congenital disease with quick onset most commonly in children, type 2 diabetes is most commonly diagnosed in older adults. But with increased prevalence of obesity, less physical activity and poor diet, type 2 diabetes is becoming more common in young adults, children and adolescents.
When treating type 2 diabetes, a first attempt is through lifestyle changes. This is followed by oral medication if increased physical activity and change in diet is not adequate. When these treatments fail, insulin injections may be needed. There are two main types of insulins, long acting insulin to lower fasting glucose levels, and fast acting insulin to lower glucose levels following food intake. Standards of Medical Care in Diabetes recommend starting with long acting insulin treatment, and adding . In this paper, we focus on treatment of type 2 diabetes with long acting insulin, specifically initiation of the long acting insulin treatment.
Initiating long acting insulin treatment is an iterative process since response to insulin is individual. Too large doses of insulin can cause low blood glucose, hypoglycemia, which in severe cases can lead to coma and even death. Health care professionals prescribe small doses and increase dose sizes over time, based on self-monitored blood glucose (SMBG), until a target glucose level is reached. SMBG measurements are glucose measurements performed by the patients by finger-pricking. Doses of long acting insulin are adjusted based on SMBG measurements performed in a fasting state, typically before breakfast. The rules by which health care professionals change dose sizes are typically represented by simple tables that do not account for the great inter-patient variability. Therefore, insulin initiation can take months to years, and in the U.S., more than 60% of type 2 diabetes patients on insulin treatment do not reach recommended treatment goals [Wong et al. 2012] .
In this paper, we wish to understand the behaviour of fasting glucose in response to long acting insulin, through a physiological model of the glucose-insulin regulatory system. Physiological models of healthy humans and people with type 1 and type 2 diabetes exist. Most models are based on the Bergman minimal model [Bergman et al. 1979 , Toffolo et al. 1980 ], but they vary in purpose and level of complexity. A number of models have been developed to simulate the regulatory system in type 1 diabetes, due to high interest in closed-loop control for this patient group [Kanderian et al. 2009 , Hovorka et al. 2004 , Dalla Man et al. 2007 . Jauslin et al. [2011] published a model for 24-hour modelling of insulin and glucose profiles in type 2 diabetes which Røge et al. [2014] used to further build a model to simulate effect of a specific type of insulin. These models are similar in that their purpose is 24-hour modelling where fast dynamics, such as increase in glucose due to meals, are well captured. In the current work we are interested in slower dynamics, as we work with fasting glucose and long acting insulin. Aradóttir et al. [2017] published a model for simulating fasting glucose during long acting insulin treatment. This model is based on a type 1 diabetes model by Kanderian et al. [2009] with an endogenous insulin production model by Ruan et al. [2015] to simulate type 2 diabetes. This model used parameters from literature, and here we wish to identify parameters from clinical data.
In Section 2 we outline the problem statement and describe important features of relevant clinical data. In Section 3 we adjust a detailed physiological model such that important parameters are identifiable from available clinical data with low sampling frequency. In Section 4 we discuss identifiability and list results from model identification based on simulated and clinical data.
STATEMENT OF THE PROBLEM
In this work we want to create a physiological model of insulin-glucose dynamics in type 2 diabetes. The purpose of this model is for control design for dose guidance in long acting insulin treatment. Such a model should have a physical interpretation, and parameter estimates based on data from a group of patients to capture variability in the patient population.
Clinical trials investigating new drugs are classified into different phases, and vary in purpose and number of participants. The first phases include only a few participants in the clinic, typically healthy volunteers, primarily aimed at testing for safety. Phase II and III studies test for efficacy and effectiveness, include hundreds or a few thousand patients and data is logged in the clinic or at home.
In Phase II and III studies on long acting insulin, glucose measuring frequency is typically one per day and sparse. The low data frequency is insufficient to identify detailed state-of-the-art models, such as the ones by Hovorka et al. [2004] or Kanderian et al. [2009] . For illustration, Figure 1 shows a four day simulation using the Kanderian et al. [2009] model, and glucose measured pre-breakfast (fasting).
Furthermore, excitation of the system in clinical trials is limited due to safety issues. Large doses of insulin can lead to hypoglycemia (too low blood glucose), a dangerous state which can lead to death. Therefore data illustrating insulin-glucose dynamics for glucose levels below 3.9 mmol/L (clinical hypoglycemia, International Hypoglycaemia Study Group [2016] ) are rare.
MODEL STRUCTURE
We use the model by Kanderian et al. [2009] , augmented in Aradóttir et al. [2017] , as a starting point. We investigate which parameters are identifiable in long acting insulin treatment in an in silico setting, and finally consider whether this is applicable in vivo.
Base model
The following model, from Kanderian et al. [2009] , describes insulin-glucose dynamics in type 1 diabetes in four re-named compartments, where the two-compartment meal model has been excluded,
After changing units to L, U, days and mmol (respectively from mL and dL, µU, min and mg), u is exogenous insulin [U/day], x 1 and x 2 denote subcutaneous and function of glucose concentration. The simplest model consists of two parts, a basal rate and a linear increase in production with elevated glucose levels. In this work, we assume a linear relationship between glucose and insulin production, so (1) becomes
where p 7 is a parameter describing glucose sensitivity of the insulin producing cells in the pancreas [U/mmol] and insulin production is assumed to increase linearly with fasting glucose. We refer to this model as the Base model.
To determine which parameters are identifiable, and for in silico data generation, we use parameter values published by Kanderian et al. [2009] . The time constant p 1 in this paper describes fast acting insulin, and can therefore not be used here. We choose a value for p 1 to roughly describe long acting insulin-glucose dynamics. The parameter describing glucose sensitivity of insulin production is a result of the other parameters, chosen such that fasting glucose has a specific value, x 4 (t = 0) = x 4,0 . Setting the last two equations of (2) equal to zero, x 1 = x 2 = 0 and rewriting, we get
which is used to determine the value for p 7 based on the mean values of the other parameters.
Modification for identifyability
The area of greatest interest is around the target glucose values, ranging from approximately 4 to 6 mmol/L. Values for x 3 in this area are of order 10. Typical values for p 5 range from an order of 10 −5 to 1. We therefore neglect this inverse time constant as it is small relative to the dynamic inverse time constant x 3 . The Base model (2) has two gains, insulin clearance rate p 2 and insulin sensitivity p 4 . Considering the assumptions in Section 2, data from * p 1 is roughly assessed based on knowledge about long acting insulin, e.g. Heise et al. [2017] describe a half-life of approximately 24 hours.
† p 7 is an estimated parameter from mean parameter values. In this work we set x 4 (0) = 8 mmol/L. This may however be chosen to fit the actual fasting glucose level at zero insulin input.
clinical trials will only contain insulin input, u, and glucose measurements, x 4 . Therefore only one gain is identifiable. We rewrite the model by settingx 
where we have reduced to one gain, a ratio between the two original gains,p 4 = p 4 /p 2 [1/U].
Discretization and model reduction
In order to determine whether the model can be reduced, we linearize the system and investigate properties of a discretization of the system. We linearize the modified model (4) such thaṫ
and x 4,ss and x 3,ss are steady state values. In this work we linearize around x 4,ss = 5 mmol/L. All eigenvalues of the matrix A have negative real parts, and the system is asymptotically stable.
Discretizing this system yields
and T s is the sampling frequency. Since in Section 2 we assume that the sampling frequency is 1/day, we investigate eigenvalues of A d for T s = 1 day for the mean parameter values in Table 1 . We observe that the real part of two eigenvalues are close to zero. This means that some time constants are not identifiable, and we may want to assume that two compartments reach steady state immediately. In the next section we residualize the modified model (4).
Residualized model
From 
We find that τ ∈ [0.05, 0.1] day which is small compared to p 1 , the time constant in the first two compartments. Therefore we assume that x 4 reaches steady state immediately following change inx 1 andx 2 . Setting (6) to zero gives a steady state expression for x 4 (after eliminating the conjugate root due to x 4 is a concentration and therefore x 4 > 0),
and the residualized model becomes
where y is the measured glucose concentration in plasma.
We refer to this model as the Residualized model. Figure 2 illustrates the output function in the area of interest (blue markers).
MODEL IDENTIFICATION
We investigate the identifiability ofp 4 , p 6 andp 7 in (8c) through the Fisher Information matrix. For values ofx 2 in the area of interest, we observe that the Fisher information matrix is nearly singular, so we can not estimate all three parameters simultaneously.
The goal is to make a model of fasting glucose in response to long acting insulin in an area of interest, where parameters and states have a physiological meaning. Inspired by the expression in (8c), we suggest estimating y = h(x 2 ) with a model of the form y = α + βx 2 + γ 1 +x 2 (9) where we might interpret α as fasting glucose at baseline [mmol/L], β as a form of insulin sensitivity [mmol·day/U·L], and γ contributes to describing glucose sensitivity of the insulin producing beta cells [day 1/2 ·mmol/L·U 1/2 ]. Figure  2 illustrates the output function h(x 2 ) for the mean parameter values in Table 1 (9) and a fit to the data generated by Base Model in (2).
Parameter estimation in CTSM-R
For model identification we use CTSM-R, Continuous Time Stochastic Modelling for R, an open source platform for identifying parameters of linear and non-linear greybox models. Given discrete time series data, CTSM-R can identify parameters of stochastic differential equations. The general model structure is a state space model on the form
(11b) where θ is an l-dimensional set of parameters to estimate, θ is the set of parameters to identify, u t is the input at time t, σ(u t , t, θ) 2 is process noise covariance matrix and w t is a Brownian motion path. y k is discrete observations and e k is the measurement error (assumed to be white Gaussian noise). The model identification is based on maximum likelihood, where the likelihood function is the joint probability density
where
is a sequence of measurements y k . CTSM-R considers stochastic differential equations that are driven by Wiener processes and so the conditional densities are approximated by Gaussian densities. A continuous-discrete extended Kalman filter is used for smoothing to determine an estimate for the measurements,
, and the innovation where k = y k −ŷ k|k−1 . The density is then
The software allows missing observations. CTSM-R outputs estimates for the parameters, initial conditions and noise, standard deviance of the estimates and the tstatistic, to name a few. The methods and software are described in more detail in [CTSM-R 2015] . 
RESULTS

Simulated data
We use CTSM-R to identify p 1 , α, β and γ from series of simulated data, generated from the Base model. We excite the system with a range of insulin injections such that fasting glucose levels span clinically relevant glucose concentrations; hyperglycemia (> 6 mmol/L), normoglycemia (< 6 mmol/L and > 3.9 mmol/L) and hypoglycemia (< 3.9 mmol/L). This is illustrated in Figure 3 . Table 2 shows the results from identifying the model (8a)-(8b) and (9) in CTSM-R using simulated data generated using the Base model. We observe that all parameter estimates are significant, although θ * is not inside the confidence interval in all cases. Figure 3 illustrates the identified model in red compared to the least squares fit to the output function (8c).
Clinical data
In a Phase III clinical trial published by Zinman et al. [2012] , 773 adult type 2 diabetes patients were initiated on insulin degludec, once daily injections. During the following months, the treatment was intensified until pre-breakfast (fasting) glucose was at a clinically recommended level. Dose sizes were adjusted once per week, based on home-logged SMPG measurements.
As mentioned in Section 2, clinical data are prone to practical issues regarding data capture and excitation. In * Confidence intervals calculated as mean ± 1.96 · SD. Fig. 4 . A cut-out from measured clinical data for one patient in the study by Zinman et al. [2012] .
the study by Zinman et al. [2012] , pre-breakfast glucose was measured and logged the last three days of the week, along with the corresponding insulin dose. Figure 4 shows a 3 week cut-out from measured data for one patient in the study. This figure illustrates the sparsity of glucose data compared to the insulin data. The full data set for the patient is illustrated in Figure 5 . Focus in the clinical trials that we consider relevant is not on system identification but rather on efficacy and safety of the drug. Therefore many data sets do not contain all the appropriate data for model identification. Notice that none of the measured data are lower than 4 mmol/L. The reason is that glucose levels below this value are clinically considered too low, and are therefore not frequently seen in clinical trials. This means that we can expect to only have data for y ≥ 3.9 mmol/L.
We use CTSM-R to estimate α, β and γ from the measured data in Figure 5 . Since p 1 is not identifiable from the data we set p 1 = 0.5 days. The resulting parameter estimates, confidence intervals and p-values are listed in Table 3 and Figure 5 illustrates the model fit. We observe that all three parameter estimates are significant. The interpretation of the parameters in Section 4 remains open for discussion. We mentioned that β could be interpreted as insulin sensitivity, and that γ could contribute to glucose sensitivity of the insulin producing beta cells. and model fit. We would expect that endogenous insulin production decreases for lower values of glucose. Therefore the total glucose lowering effect of an insulin injection is lower for low values of glucose, and the output function should level off. We might therefore consider β and γ as a combination of insulin sensitivity of the glucose elimination and glucose sensitivity of the insulin production.
CONCLUSION
This paper suggests a model of glucose-insulin dynamics in type 2 diabetes using data of low frequency. The purpose of such a model is to simulate fasting glucose levels in long acting insulin treatment, to enable control algorithm development for dose guidance. As a starting point we used the four-compartmental physiological model for 24-hour simulations of glucose concentration following meal intake and injection of fast and long acting insulin. We investigated identifiability of parameters when the sampling period is 1 day, and reduced the model to a two-compartmental model with a non-linear output function. We use the open source software CTSM-R for model identification. All parameter estimates are significant when fitting to data simulated by the six-compartmental physiological model, as well as for the chosen set of clinical data.
Design of experiment in clinical trials remains a challenge for model identification. This work is one step of many in an iterative process to making a dynamical system of insulin-glucose dynamics in long acting insulin treatment of type 2 diabetes.
